elranatamab will improve the degree or result of fentanyl transdermal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Elranatamab causes cytokine release syndrome (CRS) which will suppress exercise of CYP enzymes, causing improved publicity of CYP substrates.avapritinib and fentanyl transdermal equally boost sedation.